Fremont, CA, September 29, 2011 --(PR.com
)-- AnaSpec’s MOG (35-55) peptide from mouse and rat sequence (cat# 60130) has been shown to induce anti-MOG (35-55) autoantibody production in C57BL/6 mice at 100% incidence (10/10), indicating that this peptide is the clear choice for in vivo anti-MOG (35-55) autoantibody study.
In addition to this peptide, AnaSpec also provides a large selection of MOG peptides of varied sequences and lengths, and MBP (myelin basic protein) and PLP (proteolipid proteins) peptides, two other potential primary encephalitogenic target antigens in multiple sclerosis.
To obtain a price quote for larger quantity of the MOG (35-55) peptide, please email firstname.lastname@example.org.
For more information, please visit https://www.anaspec.com/products/promotions.asp?id=88&col=2&row=2
AnaSpec, EGT Group
AnaSpec, EGT Group is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and qPCRs. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.
For more information visit www.anaspec.com